PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11196899

Structurally diverse copper(II)-carboxylato complexes: neutral and ionic mononuclear structures and a novel binuclear structure.

G Psomas·C P Raptopoulou·L Iordanidis·C Dendrinou-Samara·V Tangoulis·D P Kessissoglou
View original source ↗Export metadata ↓

Abstract

The copper complexes with the commercial auxin herbicides MCPA, 2,4-D, and 2,4,5-T in the presence of a nitrogen donor heterocyclic ligand, phen or bipyam, were prepared and characterized. The available evidence supports a dimeric structure for the 2,4-D complex in the presence of bipyam while phen leads to monomeric forms. The EPR spectrum of Cu2(2,4-D)4(bipyam)2 at 4 K in the solid state exhibits an axial signal which corresponds to almost isolated S = 1/2 magnetic ions. Magnetic data for the dimer show a weak antiferromagnetic interaction between the two metal ions with J = -08 cm-1. The crystal structures of tetrakis[(2,4-dichlorophenoxy)acetato]bis(2,2'-bipyridylamine)dicopper(II), 1, bis(1,10-phenanthroline)[(2,4,5-trichlorophenoxy)acetato]copper(II) chloride, 2, and aqua(1,10-phenanthroline)bis[((2-methyl-4-chlorophenoxyacetato]copper(II), 3, were determined and refined by least-squares methods using three-dimensional MoK alpha data. 1 crystallizes in space group P1, in a cell of dimensions a = 10813(1) A, b = 12138(1) A, c = 11909(1) A, alpha = 86448(3) degrees, beta = 80127(3) degrees, and gamma = 63982(3) degrees, and V = 13837(2) A3, with Z = 1 2 crystallizes in space group I2/a, in a cell of dimensions a = 29958(9) A, b = 11342(3) A, c = 21196(7) A, beta = 10794(1) degrees, and V = 68522(4) A3, with Z = 8 3 crystallizes in space group P1, in a cell of dimensions a = 87419(8) A, b = 12512(1) A, c = 14598(1) A, alpha = 110737(1) degrees, beta = 95742(2) degrees, gamma = 103286(2) degrees, V = 14241(2) A3, with Z = 2.

Explore related subjects

Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G Psomas, C P Raptopoulou, L Iordanidis, C Dendrinou-Samara, V Tangoulis, D P Kessissoglou. 2000-07-10. Structurally diverse copper(II)-carboxylato complexes: neutral and ionic mononuclear structures and a novel binuclear structure.. https://doi.org/10.1021/ic991476q

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2027

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗